MAP2K7 and cancer: Mechanistically, FAK inhibition has been shown to reprogram cancer-associated fibroblasts (CAFs), suppressing the production of fibroblast growth factor-1 (FGF1), a driver of resistance to RAF-MEK inhibition [51].